NbN3 3.9.5

It has become evident that the current pharmacological nomenclature of psychotropic medications does not align with our contemporary knowledge or adequately guide clinicians in neuroscience-based prescriptions. Prescribing “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients is a common but confusing practice.

• Five international organizations - ECNP, ACNP, AsCNP, CINP & IUPHAR - joined forces five years ago to establish a taskforce with a mission to integrate current neuroscience advancements into the nomenclature.
• The overarching goal is to encompass all medications with CNS indications and assist clinicians in determining the logical "neuropsychopharmacological step."
• In the second edition, 22 new medications have been added, expanding the NbN to now include 130 medications.

The proposed nomenclature aims to mirror the existing pharmacological knowledge base without claiming final scientific truths. Rather, it serves as a progressive scientific interpretation allowing for effective patient treatment without delay.

This nomenclature is based on the following principles:

1. The immediate need for treatment.
2. Recent insights from neuroscience.
3. Expert judgments of the taskforce members.

In accordance with these principles, a comprehensive proposal has been outlined:

• Nomenclature: The analysis of Pharmacology and Mode of Action now reflects the current knowledge of targeted neurotransmitters/molecules/systems being modified and the mode/mechanism of action.
• Additional Dimensions:
  • Approved Indications: Based on recommendations from major regulatory bodies such as FDA and EMA.
  • Efficacy and Side Effects: Drawn from robust clinical data including positive single, large RCT studies. Only prevalent or life-threatening side effects are included.
  • Practical Note: Provides a summary of clinical insights curated through the taskforce's perspective.
  • Neurobiology: Focuses on the biological aspect with separate preclinical and clinical sections emphasizing the latter.

For those seeking a deeper understanding of the pharmacology, direct links to relevant IUPHAR resources are available - our partner in this initiative.

Recognizing this as an evolving process, we acknowledge the imperfections present in the current iteration. Your feedback (and that of other colleagues), coupled with new findings and reports, will drive appropriate updates in subsequent editions to refine and enhance this valuable resource.